Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
04/28/2014
Trade Name:
Delzicol
Generic Name or Proper Name (*):
mesalamine
Indications Studied:
Treatment of mildly to-moderately active ulcerative colitis
Label Changes Summary:
Approved for use in pediatric patients 12 years and older based on clinical trials conducted with mesalamine 400 mg delayed release tablets which is approved in 5-17 yearsDelzicol is bioequivalent to the mesalamine delayed-release tablets There is no age appropriate Delzicol formulation available for patients less than 12 years Safety and effectiveness of Delzicol in the maintenance of remission of ulcerative colitis in pediatric patients have not been established Information on dosingNew dosage form
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Warner Chilcott
NNPS:
FALSE'
Therapeutic Category:
Anti-Inflammatory
-
-